Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.0500 (-2.7%) ($5.0500 - $5.0500) on Tue. Jun. 22, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.68% (three month average) | RSI | 44 | Latest Price | $5.0500(-2.7%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS advances 1.4% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IPO(29%) ARKK(27%) VXX(49%) XBI(31%) ONLN(51%) | Factors Impacting ADMS price | ADMS will decline at least -1.84% in a week (0% probabilities). INDA(-52%) IVW(-99%) IWF(-48%) GLD(-46%) SPLV(-41%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.84% (StdDev 3.68%) | Hourly BBV | -1.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.13 | 5 Day Moving Average | $5.21(-3.07%) | 10 Day Moving Average | $5.13(-1.56%) | 20 Day Moving Average | $5.13(-1.56%) | To recent high | -14% | To recent low | 0.8% | Market Cap | $143m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |